

SHORT COMMUNICATION

Assessment of quality of chloroquine tablets sold by drug vendors in Abeokuta, Nigeria

O.A. IDOWU^{1*}, S.B. APALARA¹ & A.A. LASISI²

¹Department of Biological Sciences, University of Agriculture, P.M.B. 2240, Abeokuta, Nigeria; ²Department of Chemical Sciences University of Agriculture, Abeokuta, Nigeria

The control of malaria has been a major pre-occupation of man for many years. In Nigeria, malaria is holoendemic implying an all year round malaria transmission (Bruce-Chwatt, 1983) with greater intensity in the wet than the dry seasons and about 50% of the population experiencing at least one episode of malaria each year. Various measures have been put in place to reduce the scourge of malaria. One of such measures is to improve access to prompt and effective treatment and home care, which, is one of the strategies of the Roll Back Malaria (WHO, 2000). In many developing countries self-medication is a common practice (Erhun & Abayomi, 2002). This indiscriminate purchase of antimalarials from unofficial drug vendors whose drug is of doubtful quality may be a major set back for malaria control.

In Nigeria, chloroquine (CQ) is widely used in the treatment of malaria and is considered as a first line drug in treating malaria during pregnancy. The circulation of counterfeit chloroquine has been known to contribute to its resistance (Marsh *et al.*, 1999) and invariably to treatment failure thereby giving rise to the morbidity and mortality associated with malaria. Despite the efforts of the National Agency for Food and Drug Administration and Control (NAFDAC) in Nigeria, drug vendors are still circulating drugs of questionable quality. This study, therefore aimed at assessing the quality of CQ tablets sold and administered by drug vendors in Abeokuta, Nigeria.

were administered to drug vendors to obtain demographic information and assess their knowledge of malaria treatment. Questionnaires were also administered to members of the community whom buy drugs from them. Physical appearance of the tablets was examined prior to chemical analysis. Qualitative and quantitative analyses were then carried out on the tablets using colorimetry methods as described by Rogers *et al.* (1998) and Gaderton (1993). Level of significance was tested at 95% confidence level using Epi Info version 6.

Eighty percent of the drug vendors were females (age= 6–35 years) and with secondary school education (82%). Most (92.6%) of the vendors sold CQ tablets while the remaining sold various brands of sulfadoxine-pyrimethamine (SP). Seventy-two percent of the respondents were full-time vendors while 28% were into other businesses. Quality assessment of the CQ tablets purchased from the drug vendors revealed that 6% lacked the active ingredient (fake) while 32% did not contain the right quality of the active ingredients (substandard), the remaining 62% were genuine and standard.

The vendors prescribed CQ tablets differently, 84% of them gave wrong prescription to their customers while only 16% prescribed CQ correctly. It was however, observed that 50% of the correctly prescribed CQ were fake and/or substandard (Table 1) implying that only 8% of the vendors were actually

Table 1: Quality of CQ in relation to physical appearance of tablets and location of purchase

Variable	No. of fake.substandard(%)	No. of standard (%)	Total
Physical Appearance			
Smooth Tables	16 (39.0)	25 (61.0)	41
Rough Tables	3 (33.3)	6 (66.7)	9
Location			
Urban	18 (69.0)	8 (31.0)	26
Rural	13 (54.2)	11 (45.8)	24

The drug vendors were seen in market places, mechanic workshops, motor parks and some rural communities. Samples of CQ tablets were purchased from them for laboratory analysis. Questionnaires

treating malaria with standard CQ and with the right dosage.

The physical appearance of the CQ tablets was observed not to have direct effect on the quality of the

* To whom correspondence should be addressed. E-mail: etidowu@yahoo.com

drug since a higher percentage of the rough tablets were standard compared to the smooth tablet. The difference was not statistically significant ($P>0.05$). Drug vendors with primary education sold more of substandard drugs than the more educated ones (Table 2). Education also influenced positively the knowledge of CQ dosage.

Vendors with ≥ 5 years (72.7%) of experience in drug hawking business sold more of good quality drugs than those with <5 years (53.6%) of experience, but the difference was not significant ($P>0.05$). Experience did not have a positive influence on

as a result of change in treatment policy involving the increase in number of tablets to be taken for malaria treatment. Poverty and ignorance may be the reason for patronage of drug vendors. The overdose of the antipyretic drugs may have been the reason the treatments given by drug vendors were considered effective. In conclusion, for the effective control of malaria in Abeokuta and many other parts of Nigeria, the activities of drug vendors need to be moderated and monitored by health officials, and appropriate education be provided to both the drug vendors and the community at large.

Table 2: Quality of CQ sold and prescription administered in relation to education level of the vendors

Variable	Primary Education N (%)	Secondary Education N (%)	Tertiary Education N (%)	Total N (%)
Quality of CQ				
fake I Standard	2 (40.0)	15 (36.6)	2 (50.0)	19 (38.0)
Standard	3 (60.0)	26 (63.4)	2 (50.0)	31 (62.0)
Dosage				
Correct dosage	0 (0)	7 (17.1)	1 (25.0)	8 (16.0)
Incorrect dosage	5 (100)	34 (82.9)	3 (75.0)	42 (84.0)
Total	5 (10.0)	41 (82.0)	4 (8.0)	50

knowledge of CQ dosage for malaria treatment. Field observations revealed that all the prescriptions given by the vendors were with overdose of antipyretic drugs such as paracetamol, ibuprofen and aspirin.

Reason for patronage of drug vendors included availability of credit facilities, lack of functional health centres, affordability of vendors' drugs, effectiveness of their drugs and their closeness to the people.

The result obtained in this study indicates that fake/substandard CQ tablets are in circulation in Abeokuta, Nigeria. Although the vendors sold more of standard CQ tablets the poor prescription of dosage recorded in this study imply inadequate malaria treatment, which will invariably contribute to CQ resistance and malaria treatment failure in Abeokuta. Poor handling and storage may have affected the physical appearance of the CQ tablets and may have also contributed to the deterioration of some of the CQ tablets recorded in this study, hence may not be totally attributed to poor manufacturing practice. Ballereau (1997) observed that CQ stored under tropical conditions loses about 10% of its quality.

Education may have been a positive influence on the activities of the drug vendors although the negative effect of long hawking experience on dosage may be

References

- Ballereau, F. (1997) Stability of essential drugs in the field. *American Journal of Tropical Medicine and Hygiene* **57**, 31-36.
- Bruce-Chwatt, L.J (1983) Malaria and Pregnancy. *British Medical Journal* **286**, 63-76.
- Erhun, W.O. & Abayomi, A. (2002) Students' management of perceived malaria in a Nigerian University. *Journal of Social & Administrative Pharmacy* **19**, 151-160.
- Ganderton, D., Turner, A.F., Allen, W.G., Bell, A.G. & Calam, D.H. (1993) *British Pharmacopoeia: Test Procedures*. British Pharmacopoeia Commission. Volume 1: pp 33-34.
- Marsh, V.M., Mutemi, W.M., Muturi, J., Haaland, A., Watkins, W.M., Otieno, G. & Marsh, K. (1999) Changing home treatment of childhood fevers by training shop keepers in rural Kenya. *Tropical Medicine and International Health* **4**, 736-743.
- Rogers, A.R., Arrouas, M., Luszczak, E. & Schledere, E. (1998) *European Pharmacopoeia*. 2nd edition, Part II. Maisonneuve S.A. pp 54.
- WHO (2000) *Roll Back Malaria Project for the Accelerated Implementation of Malaria Control in Africa, 1997-1998*. World Health Organization, Geneva.

Information and instructions for Authors

General Information

Tanzania Health Research Bulletin is a peer-reviewed journal, which targets scientists, policy and decision makers, as well as the public. The Editorial Board welcomes contributions in the form of original research reports, review articles, short communications, commentaries or letters to the editor on health research, public health, and policy and planning.

Manuscripts should be prepared in accordance with the fifth edition of the "Uniform Requirements for Manuscripts submitted to Biomedical Journals" established by the Vancouver Group (International Committee of Medical Journal Editors, ICMJE). The complete document, updated October 2001, is available at <http://www.icmje.org/index.html>

Manuscripts are considered with the understanding that they have neither been published previously nor are under consideration by another publisher.

Preparing a manuscript

The manuscript should be organized as follows:

1. **Title.** The title should be short and to the point; omit phrases such as "Investigation on..." "Preliminary report of ..."; numbered series articles followed by a subtitle are not allowed. Taxonomic affiliation and authority should be given in the abstract, or in the key words, but not in the Title.
2. **Addresses.** Full addresses should appear under the names of the author(s); in addition, the title page should contain the name and address of the person to whom the proofs should be sent. If the author's address has changed, her/his full present address should also appear on the title page.
3. **Key words.** A short list of terms suitable for indexing should be included.
4. **Body of manuscript**
 - (a) **Abstract** (short and concise; 250 words): this should contain the full scientific name
 - (b) **Introduction:** this part should be directed to the present investigation; avoid giving a review on general aspects of the topic; number of citation should be limited.

- (c) **Materials and methods:** all information must be given so that it is quite clear how the experiments were done: any interested colleague should be able to verify the experiments from this information. However, details about already commonly used materials and methods must be omitted. Information about the origin of the source of materials is necessary.
- (d) **Results:** the results are usually presented in tables and figures, and the text must provide a clear explanation of this information. Tables and figures should only be used for substantial amounts of data, otherwise the information should be inserted in the text. Avoid repeating data from Tables and Figures in the text as much as possible.
- (e) **Discussion:** additional citations may be given here, and the findings discussed in relation to what is already known. Scientific as well as practical implications may be mentioned. Within space limitations the author has some freedom to express her/his own opinion, even if editors or referees differ with her/him.
- (f) **Tables:** Data in tables and figures should not be duplicated. They should be numbered consecutively in Arabic numerals, and bear descriptive headings. Each is to be presented individually on separate sheets. If many tables cover similar results, try to combine them. Statistical significances should be indicated with small letters after the data with a note of explanation under the table. Remember that in English data with decimals are written 7.5. Usage of more decimals than necessary should be avoided.
- (g) **Drawings:** Drawings should also be restricted and combining drawing under one caption must be considered. Figure legends should be grouped together on a separate sheet. The figures should be identified by number and name of author.
- (h) **References:** For citations in the text: use name and year system; e.g. (Magesa, 1998); for two authors, use the ampersand (&) e.g. (Mboera & Kitua, 2001); for more than two authors, use *et al.*, e.g. (Mboera *et al.*, 1999). If referring to a personal communication use initials e.g. (A.Y. Kitua, per comm.). For unpublished results, use unpubl., e.g. (Ijumba, unpubl). The later two categories, however, cannot be put in the reference list.

For citations in the reference section: list each reference alphabetically on the first author's last name; if a single author has more than one contribution, list each chronologically; in cases of more than one author, list each reference alphabetically on 2nd, 3rd, etc. author's names. Publications in preparation or submitted can only appear in the reference list if they have been accepted for publication, mentioning year of publication and volume of the journal with the reference note 'in press' added. Journal titles should be given in full.

When a scientific name of an animal or a plant is used for the first time in an article, it should be stated in full. In subsequent citations, the genus name may be abbreviated to its first letter followed by a period.

- (i) **Units, symbols and abbreviations.** Numerals are always used with abbreviated units (e.g. 3 mm² not three mm²). In all other cases, whole numbers above 10, fractions and decimals should be expressed as numerals, and whole numbers between 1 and 10 are to be spelled out in full. All

units are to conform to the standards of the International System (S.I.).

Short communications

Contributors are requested to submit short manuscripts (up to three pages in final print) as 'short communications'. A short communication contains no abstract, and can be organized either along the lines of a regular manuscript, or without subdivisions. Authors may also consider combining the results and discussion sections.

Submitting a manuscript

The manuscript should be submitted preferably by email to: The Editor, *Tanzania Health Research Bulletin*, National Institute for Medical Research, P.O. Box 9653, Dar es Salaam, Tanzania; Fax: +255 22 2121360. Email: thrb@nimr.or.tz or Imboera@nimr.or.tz